| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $176.2M | -22.9% |
| Cost of Revenue | $93.1M | -27.7% |
| Gross Profit | $83.1M | -16.6% |
| R&D Expense | $17.0M | -3.8% |
| SG&A Expense | $102.8M | -31.0% |
| Operating Income | -$36.8M | +71.9% |
| Pre-tax Income | -$32.2M | +71.7% |
| Income Tax | $1.8M | +41.0% |
| Net Income | $78.3M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $250.5M | +453.1% |
| Short-term Investments | $160.7M | -25.8% |
| Accounts Receivable | $33.4M | -27.1% |
| Inventory | $23.2M | +3.2% |
| Current Assets | $476.2M | +39.4% |
| Total Assets | $765.0M | +8.7% |
| Current Liabilities | $219.0M | +239.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.6M | +47.4% |
| Capital Expenditures | $16.4M | -4.7% |
| Investing Cash Flow | $250.3M | +41.6% |
| Financing Cash Flow | -$21.1M | +87.0% |
| Free Cash Flow | -$25.0M | +25.5% |
| +168.2% |
| EPS (Basic) | $1.40 | +156.2% |
| EPS (Diluted) | $1.40 | +156.2% |
| Total Liabilities |
| $262.4M |
| -13.0% |
| Stockholders' Equity | $502.6M | +25.1% |